STOCK TITAN

SCYNEXIS, Inc. - $SCYX STOCK NEWS

Welcome to our dedicated page for SCYNEXIS news (Ticker: $SCYX), a resource for investors and traders seeking the latest updates and insights on SCYNEXIS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SCYNEXIS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SCYNEXIS's position in the market.

Rhea-AI Summary
SCYNEXIS reported closing of exclusive license agreement with GSK for BREXAFEMME. Received $90M upfront payment and $25M milestone payment. NDA for oral ibrexafungerp tablets accepted in China. Cash balance of $91.9M with projected cash runway beyond two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
-
Rhea-AI Summary
SCYNEXIS, Inc. announced that China’s NMPA has accepted for review a New Drug Application for oral ibrexafungerp tablets for the treatment of vulvovaginal candidiasis in China. The application is based on positive Phase 3 study results, and if approved, ibrexafungerp will be a new anti-fungal treatment for Chinese patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
none
-
Rhea-AI Summary
SCYNEXIS achieves $25 million development milestone for ibrexafungerp in invasive candidiasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
SCYNEXIS, Inc.

Nasdaq:SCYX

SCYX Rankings

SCYX Stock Data

69.70M
37.27M
2.84%
48.35%
2.59%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
JERSEY CITY

About SCYX

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.